Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2002
03/12/2002US6355483 Antisense nucleotides for use in the treatment of leukemia
03/12/2002US6355479 Insect polypeptide for use in the treatment of autoimmune diseases, allergies and cancer
03/12/2002US6355463 UDP-N-acetylenolpyruvylglucosamine reductase
03/12/2002US6355460 Detecting enzyme inhibitors; incubate enzyme with modulator, monitor sample for reduction in enzyme activity, reduction in enzyme activity indicates modulator
03/12/2002US6355451 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
03/12/2002US6355446 DocosahexAenoic acid as retinoid X-receptor ligand and uses thereof
03/12/2002US6355418 Chimeric oligonucleotides and uses thereof in the identification of antisense binding sites
03/12/2002US6355274 Encapsulated long chain alcohols
03/12/2002US6355270 Particles for oral delivery of peptides and proteins
03/12/2002US6355269 Oral compositions of levosimendan
03/12/2002US6355268 Liposome-entrapped topoisomerase inhibitors
03/12/2002US6355266 Indomethacin-containing patch; for theray of pain due to contusion, sprain or muscular fatigue, and pain associated with shoulder stiffness
03/12/2002US6355261 Ultraviolet radiation absorbing waxes useful in cosmetic compositions
03/12/2002US6355259 Cosmetic composition for skin comprising urea
03/12/2002US6355258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form
03/12/2002US6355257 Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
03/12/2002US6355254 Pathogenic Escherichia coli associated protein EspA
03/12/2002US6355251 Compositions and methods for epidermal chemexfoliation
03/12/2002US6355241 In vivo production and delivery of erythropoietin
03/12/2002CA2347330C Liquid injectable formulation of disodium pamidronate
03/12/2002CA2313783C Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof
03/12/2002CA2235625C Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation
03/12/2002CA2200773C Process for reducing light-induced blueing in cosmetic compounds containing titanium oxide pigments and in compounds and applications
03/12/2002CA2187214C Aminostilbazole derivative and medicine
03/12/2002CA2137889C Eburnan analogs; process for preparing the same and pharmaceutical compositions containing them
03/12/2002CA2099262C (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl]hydrazono]propanedinitrile
03/12/2002CA2086438C Anti-herpes virus and cytomegalovirus oligomers
03/12/2002CA2060393C Carbamic acid derivatives and method for preparing the same
03/12/2002CA2055947C Condensed heterocyclic compounds, their production and use
03/12/2002CA2053527C Pyridine derivatives, their production and use
03/12/2002CA2047944C Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained
03/11/2002CA2356466A1 Pharmaceutical preparations containing soy isoflavone extracts and probiotic micro-organisms
03/07/2002WO2002019213A2 Method for treatment of migraine using pde5 inhibitors
03/07/2002WO2002018941A2 Screen for glutamate reuptake inhibitors, stimulators, and modulators
03/07/2002WO2002018938A1 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
03/07/2002WO2002018909A2 Single riser/single capillary blood viscometer using mass detection or column height detection
03/07/2002WO2002018637A2 Diagnosis and treatment of prostate cancer
03/07/2002WO2002018632A2 Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
03/07/2002WO2002018619A2 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response
03/07/2002WO2002018608A2 Methods for enhancing the efficacy of cancer therapy
03/07/2002WO2002018593A2 Modulation of fas and fasl expression
03/07/2002WO2002018540A2 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
03/07/2002WO2002018449A1 Nitroderivatives of polysaccharides
03/07/2002WO2002018440A1 Anti-angiogenic peptides
03/07/2002WO2002018404A2 Nucleoside derivatives for the treatment of hepatitis c
03/07/2002WO2002018395A1 Phosphate derivatives as immunoregulatory agents
03/07/2002WO2002018390A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
03/07/2002WO2002018389A2 Thienopyrimidine
03/07/2002WO2002018387A1 2,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonvulsive action and methods for producing the same
03/07/2002WO2002018386A1 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES
03/07/2002WO2002018385A1 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES
03/07/2002WO2002018384A1 Process for the preparation of vitronectin receptor antagonists
03/07/2002WO2002018383A2 Aza heterocyclic derivatives and their therapeutic use
03/07/2002WO2002018382A1 Pyrazolopyridine compound and pharmaceutical use thereof
03/07/2002WO2002018381A1 6,7-dihydro-pyrrolo[3,4-b]pyridin-5-ones with an anticonvulsive action and methods for producing the same
03/07/2002WO2002018380A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
03/07/2002WO2002018379A2 7-oxo pyridopyrimidines
03/07/2002WO2002018377A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
03/07/2002WO2002018374A1 Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
03/07/2002WO2002018373A1 Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
03/07/2002WO2002018371A1 Nucleoside metabolism inhibitors
03/07/2002WO2002018370A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
03/07/2002WO2002018369A2 Peptidomimetic protease inhibitors
03/07/2002WO2002018368A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
03/07/2002WO2002018367A1 Tetrahydrobenzindole derivatives capable of binding to 5-ht7 receptor and metabolically stable
03/07/2002WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai
03/07/2002WO2002018358A1 N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
03/07/2002WO2002018355A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
03/07/2002WO2002018353A2 Oxazolidinone chemotherapeutic agents
03/07/2002WO2002018348A2 Quinazoline derivatives as alpha-1 adrenergic antagonists
03/07/2002WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors
03/07/2002WO2002018345A1 Quinoline antibacterial compounds and methods of use thereof
03/07/2002WO2002018344A1 Novel ester or amide derivatives
03/07/2002WO2002018343A1 Method for synthesizing flosequinan from 4-fluoroanthranilic acid
03/07/2002WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS
03/07/2002WO2002018333A1 Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
03/07/2002WO2002018330A1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
03/07/2002WO2002018327A2 Guanidinobenzamides as mc4-r agonists
03/07/2002WO2002018324A2 Immunoregulatory compounds, derivatives thereof and their use
03/07/2002WO2002018320A2 INHIBITORS OF α4 MEDIATED CELL ADHESION
03/07/2002WO2002018310A1 Method of obtaining a hydroxytyrosol-rich composition from vegetation water
03/07/2002WO2002017971A1 Slow release pharmaceutical preparation and method of administering same
03/07/2002WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women
03/07/2002WO2002017966A1 Antacid chewing gum products coated with high viscosity materials
03/07/2002WO2002017963A2 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
03/07/2002WO2002017958A1 Agent for influencing angiogenesis
03/07/2002WO2002017954A1 Antiparkinsonism drugs
03/07/2002WO2002017952A2 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
03/07/2002WO2002017949A2 Novel functions for dp214
03/07/2002WO2002017945A1 Efficient method for producing compositions enriched in anthocyanins
03/07/2002WO2002017944A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders
03/07/2002WO2002017943A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain
03/07/2002WO2002017942A1 Use of a composition comprising an extract of pollen for the treatment of irritability
03/07/2002WO2002017941A1 Use of a composition comprising an extract of pollen for the treatment of edema
03/07/2002WO2002017940A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria
03/07/2002WO2002017939A1 A composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from glycyrrhiza glabra
03/07/2002WO2002017933A1 Trace elements
03/07/2002WO2002017932A1 Oct preparations
03/07/2002WO2002017931A1 Use of tripterygium wilfordii hook.f's extracts for preparation of medicaments for preventing and treating nervous system disorde rs
03/07/2002WO2002017930A2 Glucocorticoid blocking agents for increasing blood-brain barrier permeability